See how AbbVie Inc. and JPMorgan Chase & Co. differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
JPMorgan Chase & Co. is a leading global financial services company operating in 66 countries with more than 318,000 employees as of year-end 2025. Through its JPMorgan brands, the bank holding company reported a $4.9 trillion balance sheet and $2.68 trillion in deposits as of March 2026. Revenue is generated across three main business segments: Consumer & Community Banking, Commercial & Investment Bank, and Asset & Wealth Management. The firm holds the top global position in investment banking fees with an 8.4% market share, serves millions of customers through more than 5,000 U.S. branches, and oversees over $7.1 trillion in client assets in its wealth and asset management business.